bioRxiv / medRxiv
open access
First-week expansion of activated peripheral B-cell subsets is associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab
BackgroundAlthough immune checkpoint inhibitors (ICIs) cause grade 3 or higher immune-related adverse events (irAEs), validated biomarkers for identifying patients at risk of these events are lacking. Given the potential contribution of B-cells to irAE development, we evaluated whether early changes
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors#1088261
- Cytokines and immunologic checkpoint molecules in predicting success of allergen immunotherapy.#209408
- Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer#969666
- Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma#1103715
- A Study of BEN301 Injection in the Treatment of Autoimmune Diseases#834221
Record · ID 1319275
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive